Results 31 to 40 of about 303,481 (268)

The immune checkpoint ICOSLG is a relapse-predicting biomarker and therapeutic target in infant t(4;11) acute lymphoblastic leukemia

iScience, 2022
Summary: The most frequent genetic aberration leading to infant ALL (iALL) is the chromosomal translocation t(4;11), generating the fusion oncogenes KMT2A:AFF1 and AFF1:KMT2A, respectively.
Marius Külp, Anna Lena Siemund, Patrizia Larghero, Alissa Dietz, Julia Alten, Gunnar Cario, Cornelia Eckert, Aurélie Caye-Eude, Hélène Cavé, Michela Bardini, Giovanni Cazzaniga, Paola De Lorenzo, Maria Grazia Valsecchi, Laura Diehl, Halvard Bonig, Claus Meyer, Rolf Marschalek   +16 more
doaj   +1 more source

Targeting p38α in cancer: challenges, opportunities, and emerging strategies

Molecular Oncology, EarlyView.
p38α normally regulates cellular stress responses and homeostasis and suppresses malignant transformation. In cancer, however, p38α is co‐opted to drive context‐dependent proliferation and dissemination. p38α also supports key functions in cells of the tumor microenvironment, including fibroblasts, myeloid cells, and T lymphocytes.
Angel R. Nebreda
wiley   +1 more source

Proteomic Comparison of Acute Myeloid Leukemia Cells and Normal CD34⁺ Bone Marrow Cells: Studies of Leukemia Cell Differentiation and Regulation of Iron Metabolism/Ferroptosis

Proteomes
Acute myeloid leukemia (AML) is an aggressive bone marrow malignancy that can be cured only by intensive chemotherapy possibly combined with allogeneic stem cell transplantation.
Frode Selheim, Elise Aasebø, Håkon Reikvam, Øystein Bruserud, Maria Hernandez-Valladares   +4 more
doaj   +1 more source

Correlation of the differential expression of PIK3R1 and its spliced variant, p55α, in pan‐cancer

Molecular Oncology, EarlyView.
PIK3R1 undergoes alternative splicing to generate the isoforms, p85α and p55α. By combining large patient datasets with laboratory experiments, we show that PIK3R1 spliced variants shape cancer behavior. While tumors lose the protective p85α isoform, p55α is overexpressed, changes linked to poorer survival and more pronounced in African American ...
Ishita Gupta, Yang Song, Madeleine Ndahayo, Anirudh Saxena, Theresa Guo, Dylan Z. Kelley, Jessica Gore, Andrew Hennigan, Alexa Anderson, John C. Papadimitriou, Daria A. Gaykalova   +10 more
wiley   +1 more source

Frequency of polymorphisms in the IKZF1 and CDKN2A/2B genes and descriptive analysis in pediatric patients with acute lymphoblastic leukemia: a multicenter hospital-based prevalence study in Rio De Janeiro

BMC Cancer
Background Acute lymphoblastic leukemia (ALL) is the most common childhood cancer, and B-cell ALL (B-ALL) is the most common subtype. The understanding of ALL has advanced significantly in recent years due to genomic sequencing, which has made it ...
Ariadne da Rocha Figueiredo, Thayana da Conceição Barbosa, Mariana Emerenciano, Marcelo Gerardin Poirot Land   +3 more
doaj   +1 more source

Impact of leukemia subtype and demographics on patient quality of life in 76 countries: a cross-sectional study

Frontiers in Hematology
BackgroundDisease-specific factors associated with decreased quality of life (QoL) in patients with leukemia have not been studied in a large-scale, global, observational study.MethodsThis cross-sectional study used the validated Hematological Malignancy
Sam Salek, Samantha Nier, Zack Pemberton-Whiteley, Tatyana Ionova, Giuseppe Ianni, Giovanni Tripepi, Nick York, Nicole Schroeter, Kathryn Huntley, Michael Rynne, Denis Costello, Lidija Pecova, Esther Natalie Oliva   +12 more
doaj   +1 more source

Acute Lymphoblastic Leukemia [PDF]

Journal of the National Comprehensive Cancer Network, 2012
The inaugural NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for acute lymphoblastic leukemia (ALL) were developed as a result of meetings convened by a multi-disciplinary panel of experts in 2011. These NCCN Guidelines provide recommendations on the diagnostic evaluation and workup for ALL, risk assessment, risk-stratified treatment ...
Joseph C, Alvarnas, Patrick A, Brown, Patricia, Aoun, Karen Kuhn, Ballen, Naresh, Bellam, William, Blum, Michael W, Boyer, Hetty E, Carraway, Peter F, Coccia, Steven E, Coutre, Jennifer, Cultrera, Lloyd E, Damon, Daniel J, DeAngelo, Dan, Douer, Haydar, Frangoul, Olga, Frankfurt, Salil, Goorha, Michael M, Millenson, Susan, O'Brien, Stephen H, Petersdorf, Arati V, Rao, Stephanie, Terezakis, Geoffrey, Uy, Meir, Wetzler, Andrew D, Zelenetz, Maoko, Naganuma, Kristina M, Gregory   +26 more
openaire   +2 more sources

Circular RNA expression landscapes in myelodysplastic neoplasms: Associations with mutational signatures and disease progression

Molecular Oncology, EarlyView.
In this explorative study, the abundance of circular RNA molecules in bone marrow stem cells was found to be elevated in patients with high‐risk myelodysplastic neoplasms, and to be associated with an increased risk of progression to acute myeloid leukemia.
Eileen Wedge, Morten Tulstrup, Gabriele Todisco, Pedro Moura, Christophe Côme, Jakob Werner Hansen, Jakob Schmidt Jespersen, Balthasar Schlotmann, Maria Creignou, Mette Dahl, Claudia Schöllkopf, Klas Raaschou‐Jensen, Krister Wennerberg, Bo Porse, Joachim Weischenfeldt, Eva Hellström‐Lindberg, Lasse Sommer Kristensen, Kirsten Grønbæk   +17 more
wiley   +1 more source

Disease and treatment burden in patients with leukaemia: family members/partner perspective

Frontiers in Hematology
BackgroundLeukaemia patients require comprehensive care, including treatment, hospital visits, and family support. An awareness of the impact of leukaemia on family members is crucial. The Acute Leukemia Advocates Network, Chronic Lymphoid Leukemia (CLL)
Esther Natalie Oliva, Tatyana Ionova, Samantha Nier, Zack Pemberton-Whiteley, Zack Pemberton-Whiteley, Nick York, Denis Costello, Sam Salek   +7 more
doaj   +1 more source

RNA INTERFERENCE (RNAI): AN EFFECTIVE WAY TO DEVELOP RATIONAL COMBINATION THERAPIES WITH HYPOMETHYLATING AGENTS IN ACUTE LEUKAEMIAS AND MYELODYSPLASTIC SYNDROME [PDF]

European Medical Journal Hematology, 2013
Therapeutic progress in aggressive myeloid malignancies such as acute myeloid leukaemia (AML), myelodysplastic syndrome (MDS) and advanced myeloproliferative neoplasm (MPNs) has been slow.
Raoul Tibes
doaj